Search Results - "MARTIN, Tyler J"

Ultrafiltration Membranes Enhanced with Electrospun Nanofibers Exhibit Improved Flux and Fouling Resistance by Dobosz, Kerianne M, Kuo-Leblanc, Christopher A, Martin, Tyler J, Schiffman, Jessica D

“…In this study, we have improved membrane performance by enhancing ultrafiltration membranes with electrospun nanofibers. The high-porosity nanofiber layer…”
Get full text

Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy by PRICE, Sally A, DENT, Carolyn, TOMLINSON, David R, DURAN-JIMENEZ, Beatriz, YUXIN LIANG, LEI ZHANG, REBAR, Edward J, CASE, Casey C, GREGORY, Philip D, MARTIN, Tyler J, KAYE SPRATT, S

“…Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy Sally A. Price 1 , Carolyn…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age by Heyward, William L, Kyle, Michael, Blumenau, Joseph, Davis, Matthew, Reisinger, Keith, Kabongo, Martin L, Bennett, Sean, Janssen, Robert S, Namini, Hamid, Martin, J. Tyler

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in adults 40–70 years old. • 2 doses of HBsAg-1018 demonstrated superior seroprotection to 3…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus by Janssen, Julia M, Heyward, William L, Martin, J. Tyler, Janssen, Robert S

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in CKD and diabetes. • HBsAg-1018 induced superior seroprotection to HBsAg-Eng. • The safety…”
Get full text

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age by Halperin, Scott A, Ward, Brian, Cooper, Curtis, Predy, Gerald, Diaz-Mitoma, Francisco, Dionne, Marc, Embree, Joanne, McGeer, Allison, Zickler, Paul, Moltz, Karl-Heinz, Martz, René, Meyer, Ingo, McNeil, Shelly, Langley, Joanne M, Martins, Eduardo, Heyward, William L, Martin, J. Tyler

“…Highlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that…”
Get full text

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease by Janssen, Robert S, Mangoo-Karim, Roberto, Pergola, Pablo E, Girndt, Matthias, Namini, Hamid, Rahman, Sophia, Bennett, Sean R, Heyward, William L, Martin, J. Tyler

“…Highlights • Phase 3 trial of investigational hepatitis B vaccine in chronic kidney disease. • HBsAg-1018 induced superior seroprotection to HBsAg-Eng. •…”
Get full text

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults by Halperin, Scott A, McNeil, Shelly, Langley, Joanne M, Smith, Bruce, MacKinnon-Cameron, Donna, McCall-Sani, Robyn, Heyward, William L, Martin, J. Tyler

“…Highlights ► A 0–4-week schedule of HBV-ISS was as well tolerated as a 0–8-week schedule. ► 2 doses of HBV-ISS at 0–4-week achieved similar seroprotection as a…”
Get full text

Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine by Halperin, Scott A., Ward, Brian J., Dionne, Marc S, Langley, Joanne M., McNeil, Shelly A., Smith, Bruce, MacKinnon-Cameron, Donna, Heyward, William L., Martin, J. Tyler

“…An additional one to three doses of hepatitis B vaccine are recommended for nonresponders to an initial standard three-dose series. We compared the safety and…”
Get full text

Roundtable by Martin, J. Tyler

Get full text

77: Safety and Immunogenicity of a Novel Hepatitis B Vaccine Adjuvanted With Immunostimulatory Sequence (ISS) in Renal Predialysis and Dialyis Patients by de Boer, Alberdina W, McNeil, Shelly, Halperin, Scott A, Hart, Randy, Miller, Mark A, Lipman, Mark, Soroka, Steven D, Martin, J. Tyler

Get full text

The Novartis Approach to Gene Therapy by Martin, J. Tyler

Get full text

Development of an Adjuvant to Enhance the Immune Response to Influenza Vaccine in the Elderly by Martin, J.Tyler

“…Elderly persons typically show diminished immune responsiveness to influenza vaccination. Chiron Vaccines has developed a novel oil-in-water adjuvant emulsion,…”
Get full text

A rapid in vitro test for chloroquine-resistant Plasmodium falciparum by Gluzman, I Y, Krogstad, D J, Orjih, A U, Nkangineme, K, Wellems, T E, Martin, J T, Schlesinger, P H

“…We report a rapid (2-3 hr) in vitro test for chloroquine resistance in Plasmodium falciparum. The test is based on the inhibition of chloroquine efflux by…”
Get more information